The WHO said funding should be maintained for programmes like PEPFAR, which provides HIV treatment and testing to millions of people worldwide. View on euronews

The State Department issued a waiver for lifesaving aid, but HIV clinics remain shut and uncertainty lingers over the future of PEPFAR, which has saved 25 million lives.

The World Health Organization (WHO) expresses deep concern on the implications of the immediate funding pause for HIV programmes in low- and middle-income countries.

The World Health Organization on Tuesday urged the United States to reconsider its decision to suspend funding for HIV treatment programs in developing countries, after President Donald Trump ordered a freeze on foreign aid.

We call on the United States government to enable additional exemptions to ensure the delivery of lifesaving HIV treatment and care,' says UN agency - Anadolu Ajansı

The President's Emergency Plan for AIDS Relief has provided life-saving treatment to tens of millions since it was established in 2003

A recent flurry of executive orders and surprise actions by the Trump administration have roiled WHO, the CDC and the international public health community.

As President Donald Trump uses his executive authority to smash and slash programs that do not conform to his America First ideals, the President’s Emergency Plan for AIDS Relief (PEPFAR) was yet another foreign aid program put on the chopping block for a 90-day period.

The Trump administration's freeze on U.S. foreign aid has halted the distribution of lifesaving HIV medications.

A move by the Trump administration to freeze funding for PEPFAR, the widely heralded international HIV/AIDS program, is putting countless lives at immediate risk, experts say.

The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of people worldwide. "I don't think there's a lot of logic in stopping these programmes,

A unique reaction in which antibodies bind to other antibodies may help scientists at Scripps Research better understand how to design a vaccine